Investigating a new treatment target for non-small cell lung cancer
Official title: Evaluation of PARP7 dependency as a novel therapeutic target for non-small cell lung cancer
Funded at VA Greater Los Angeles Healthcare System · NIH-10695528 · Data updated 2026-11-12
This study is looking at a protein called PARP7 to see if targeting it can help boost the immune system's fight against non-small cell lung cancer, with the goal of finding better treatments for patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | VA Greater Los Angeles Healthcare System NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | October 1, 2024 |
| Project end | September 30, 2028 |
| Funding year | 2025 |
| NIH project number | 1I01CX002563-01A1 |
| Project ID | NIH-10695528 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with non-small cell lung cancer, particularly those who may not have responded well to existing therapies.
✕Less likely to help
Patients with other types of lung cancer or those whose tumors do not exhibit PARP7 dependency may not benefit from this research.
What this research studies
This research focuses on understanding the role of PARP7, a specific protein, in non-small cell lung cancer (NSCLC), which is a common type of lung cancer. The study aims to evaluate how targeting PARP7 can enhance the body's immune response against tumors and improve treatment outcomes. By analyzing the dependency of NSCLC tumors on PARP7, researchers hope to develop a diagnostic platform and therapeutic strategies that could lead to more effective treatments for patients. The approach combines bioinformatics and clinical assessments to identify patients who may benefit from this targeted therapy.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with non-small cell lung cancer.
How similar studies have gone: Previous research has shown promising results in targeting similar pathways in cancer treatment, indicating potential for success in this novel approach.
Where this research is happening
-
VA Greater Los Angeles Healthcare System
Los Angeles, United States Active
Researchers
- Principal investigator: Dubinett, Steven M. — VA Greater Los Angeles Healthcare System
- Study coordinator: Dubinett, Steven M.
Related research
Other NIH-funded projects on the same topics.
-
ABL kinase signaling and DNA collisions in small cell lung cancer
A drug target study in small cell lung cancer explores how blocking ABL kinase affects conflicts between transcription and DNA replication, which could influence tumor growth and survival.
-
XRN1 as a potential therapy target in lung cancer
A scientist-led program will study a cellular gene called XRN1 to see if turning it off can help treat non-small cell lung cancer.
-
Intermittent fasting with PD-1 inhibitors for non-small cell lung cancer
This grant tests whether a fasting-mimicking diet can boost the effectiveness of PD-1 inhibitors for people with non-small cell lung cancer.
-
Targeting STRAP to curb NSCLC spread with nanoparticle therapy
Aimed at non-small cell lung cancer, this grant tests how blocking a protein called STRAP with nanoparticles could slow cancer spread and make chemotherapy work better.
-
Modeling tumor differences to guide new treatments for resistant small cell lung cancer
A study aims to understand why some small cell lung cancer tumors resist treatment and use those insights to develop new targeted therapies.
-
TP53-mutant NSCLC: how epigenetic viral mimicry could boost immune therapy
A research grant exploring how p53 mutations in non-small cell lung cancer affect responses to a viral mimicry-based epigenetic therapy, with the goal of improving immune therapy outcomes for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.